Lurbinectedin is a new drug that has shown promising results in the treatment of various types of cancer, including breast cancer. However, there is currently limited data available on how it compares to other breast cancer treatments [1].

According to a study published in the Journal of Clinical Oncology, Lurbinectedin has shown efficacy in the treatment of metastatic breast cancer, especially in patients who have previously received chemotherapy [2]. The study found that Lurbinectedin had a response rate of 31.8% in patients who had received prior chemotherapy, compared to a response rate of 16.7% in patients who had not received prior chemotherapy.

While Lurbinectedin has shown promising results in the treatment of breast cancer, it is important to note that it is still a relatively new drug and more research is needed to determine its long-term efficacy and safety. Additionally, Lurbinectedin is not currently approved by the FDA for the treatment of breast cancer, although it has been approved for the treatment of small cell lung cancer [3].

In conclusion, Lurbinectedin has shown promising results in the treatment of metastatic breast cancer, particularly in patients who have previously received chemotherapy. However, more research is needed to determine its long-term efficacy and safety, and it is not currently approved by the FDA for the treatment of breast cancer.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://www.onclive.com/view/lurbinectedin-adds-complexity-to-second-line-treatment-selection-in-extensive-stage-small-cell-lung-cancer